136 related articles for article (PubMed ID: 36990534)
1. Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines.
Bacolod MD; Fisher PB; Barany F
Adv Cancer Res; 2023; 158():233-292. PubMed ID: 36990534
[TBL] [Abstract][Full Text] [Related]
2. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
[TBL] [Abstract][Full Text] [Related]
3. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
7. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities.
Ashrafizadeh M; Mirzaei S; Hashemi F; Zarrabi A; Zabolian A; Saleki H; Sharifzadeh SO; Soleymani L; Daneshi S; Hushmandi K; Khan H; Kumar AP; Aref AR; Samarghandian S
Biomed Pharmacother; 2021 Sep; 141():111824. PubMed ID: 34175815
[TBL] [Abstract][Full Text] [Related]
8. The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent.
Kingston DG; Snyder JP
Acc Chem Res; 2014 Aug; 47(8):2682-91. PubMed ID: 25052294
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Imai H; Komine K; Takahashi S; Saijo K; Okada Y; Kobayashi A; Okita A; Chikamatsu S; Kasahara Y; Takahashi M; Oishi T; Shirota H; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(5):262-8. PubMed ID: 27043795
[TBL] [Abstract][Full Text] [Related]
10. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.
Kenicer J; Spears M; Lyttle N; Taylor KJ; Liao L; Cunningham CA; Lambros M; MacKay A; Yao C; Reis-Filho J; Bartlett JM
BMC Cancer; 2014 Oct; 14():762. PubMed ID: 25312014
[TBL] [Abstract][Full Text] [Related]
13. Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols.
Mugabe C; Liggins RT; Guan D; Manisali I; Chafeeva I; Brooks DE; Heller M; Jackson JK; Burt HM
Int J Pharm; 2011 Feb; 404(1-2):238-49. PubMed ID: 21093563
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
Andriguetti NB; Raymundo S; Antunes MV; Perassolo MS; Verza SG; Suyenaga ES; Linden R
Curr Med Chem; 2017; 24(33):3559-3582. PubMed ID: 28641556
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study.
Firoozi MR; Sadeghi-Mohammadi S; Asadi M; Shekari N; Seyed Nejad F; Alizade-Harakiyan M; Soleimani Z; Zarredar H
Cell Biochem Funct; 2024 Jan; 42(1):e3919. PubMed ID: 38269512
[TBL] [Abstract][Full Text] [Related]
16. Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
Orth M; Unger K; Schoetz U; Belka C; Lauber K
Oncogene; 2018 Jan; 37(1):52-62. PubMed ID: 28869599
[TBL] [Abstract][Full Text] [Related]
17. The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells.
Jackson J; Leung D; Burt H
Ultrasonics; 2020 Feb; 101():106033. PubMed ID: 31561207
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Urakami S; Yoshino T; Kikuno N; Imai S; Honda S; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Urology; 2005 Mar; 65(3):543-8. PubMed ID: 15780373
[TBL] [Abstract][Full Text] [Related]
19. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
[TBL] [Abstract][Full Text] [Related]
20. Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
Ashrafizadeh M; Ahmadi Z; Mohamadi N; Zarrabi A; Abasi S; Dehghannoudeh G; Tamaddondoust RN; Khanbabaei H; Mohammadinejad R; Thakur VK
Int J Biol Macromol; 2020 Feb; 145():282-300. PubMed ID: 31870872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
